Guardant Health (NASDAQ:GH) Issues Earnings Results

Guardant Health (NASDAQ:GHGet Rating) posted its quarterly earnings data on Thursday. The company reported ($2.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.25) by ($1.00), Briefing.com reports. Guardant Health had a negative net margin of 107.20% and a negative return on equity of 62.68%. The company had revenue of $109.14 million for the quarter, compared to the consensus estimate of $105.14 million. During the same quarter last year, the company earned ($0.96) earnings per share. The company’s revenue was up 18.5% compared to the same quarter last year. Guardant Health updated its FY 2022 guidance to EPS.

Guardant Health Price Performance

Guardant Health stock traded up $1.83 during trading hours on Friday, hitting $52.92. 1,883,904 shares of the company traded hands, compared to its average volume of 1,278,413. The firm has a market cap of $5.39 billion, a P/E ratio of -12.84 and a beta of 0.81. The company has a quick ratio of 4.71, a current ratio of 4.87 and a debt-to-equity ratio of 2.13. The firm’s 50-day simple moving average is $44.52 and its two-hundred day simple moving average is $54.80. Guardant Health has a 1-year low of $27.65 and a 1-year high of $133.82.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. OTR Global downgraded shares of Guardant Health to a “positive” rating in a research report on Monday. Piper Sandler assumed coverage on shares of Guardant Health in a research report on Thursday, June 2nd. They issued an “overweight” rating and a $65.00 price target on the stock. Finally, Citigroup reduced their price target on shares of Guardant Health from $120.00 to $100.00 in a research report on Friday, May 6th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Guardant Health currently has a consensus rating of “Buy” and an average target price of $131.73.

Hedge Funds Weigh In On Guardant Health

Several large investors have recently bought and sold shares of the stock. Guggenheim Capital LLC grew its stake in shares of Guardant Health by 40.8% in the 1st quarter. Guggenheim Capital LLC now owns 101,011 shares of the company’s stock worth $6,691,000 after purchasing an additional 29,270 shares during the last quarter. Neuberger Berman Group LLC boosted its holdings in shares of Guardant Health by 8.7% in the first quarter. Neuberger Berman Group LLC now owns 92,700 shares of the company’s stock worth $6,139,000 after buying an additional 7,439 shares during the period. UBS Group AG boosted its holdings in shares of Guardant Health by 18.4% in the first quarter. UBS Group AG now owns 46,564 shares of the company’s stock worth $3,084,000 after buying an additional 7,233 shares during the period. Mirabella Financial Services LLP acquired a new position in shares of Guardant Health in the first quarter worth about $3,074,000. Finally, Capital Group International Inc. CA boosted its holdings in shares of Guardant Health by 55.6% in the first quarter. Capital Group International Inc. CA now owns 45,150 shares of the company’s stock worth $2,991,000 after buying an additional 16,132 shares during the period. Institutional investors and hedge funds own 93.69% of the company’s stock.

About Guardant Health

(Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

See Also

Earnings History for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.